2937.12.00.00/Insulin Glulisine (Apidra)/Japan

Insulin Glulisine (Apidra) from Japan

Ultra-rapid acting insulin analogue with glycine/lysine modifications at B-chain. HTS 2937.12.00.00 covers rDNA-produced structural analogues used primarily as polypeptide hormones.

Duty Rate — Japan → United States

15%

Rate breakdown

9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate

9903.05.860%Universal product exemption (U.S. note 52(b))

9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)

Calculate with your customs value Verify classification with AI

Import Tips

• Sequence analysis certificate confirming glulisine modifications essential

• Maintain refrigerated conditions; ultra-rapid analogues have narrow stability window

• API vs finished product distinction critical for correct HTS classification